

**Supplemental Table S2.** Baseline Laboratory Parameters and Cardiovascular Risk Factors (Full Analysis Set, Month 6 Primary Analysis)

Variable	Placebo (n=33)	Romosozumab 210 mg SC QM (n=34)	All (n=67)
Calcium (corrected by albumin), mg/dL	9.38±0.31	9.47±0.37	9.43±0.34
Phosphorus, mg/dL	3.8±0.42	3.89±0.34	3.84±0.38
Creatinine, mg/dL	0.73±0.17	0.71±0.11	0.72±0.14
eGFR, mL/min/1.73 m <sup>2</sup>	83.64±19.04	85.41±15.68	84.54±17.3
Cardiovascular risk factors <sup>a</sup>			
Age group, yr			
<75	26 (78.8)	30 (88.2)	56 (83.6)
≥75	7 (21.2)	4 (11.8)	11 (16.4)
Smoking history			
Current/former	1 (3.0)	0 (0.0)	1 (1.5)
Never	32 (97.0)	34 (100.0)	66 (98.5)
Unknown	0	0	0
Any history of cardiovascular risk factors			
Hypercholesterolemia	17 (51.5)	18 (52.9)	35 (52.2)
Hypertension	16 (48.5)	8 (23.5)	24 (35.8)
Diabetes	13 (39.4)	15 (44.1)	28 (41.8)
Cardiovascular disease	17 (51.5)	10 (29.4)	27 (40.3)
CNS vascular disorder	6 (18.2)	2 (5.9)	8 (11.9)

Values are expressed as mean ± standard deviation or number (%). Percentages are based on the number of patients randomized.

SC, subcutaneous; QM, once monthly; eGFR, estimated glomerular filtration rate; CNS, central nervous system.

<sup>a</sup>A history of cardiovascular risk factors was assessed based on the Medical History electronic case report form relating to a history of diabetes, hypertension, hypercholesterolemia, cardiac disorder System Organ Class (SOC), vascular disorder SOC, and CNS vascular disorders High-Level Group Term (HLGT) in Medical Dictionary for Regulatory Activities (MedDRA) version 20.1. The incidences may not sum to the total as patients can have more than one cardiovascular risk factor.